Overview

Desidustat in the Treatment of Anemia in CKD

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted over a period of up to 30 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Cadila Healthcare Limited

Treatments:

Darbepoetin alfa